China SXT Pharmaceuticals (SXTC) Other Non-Current Assets (2019 - 2024)

China SXT Pharmaceuticals (SXTC) has reported Other Non-Current Assets for 6 consecutive years, with $8.5 million the latest figure, recorded in Q3 2024.

• Quarterly Other Non-Current Assets changed N/A year-over-year to $8.5 million in Q3 2024, while the trailing twelve-month figure through Sep 2024 was $8.5 million (changed N/A YoY) and the FY2024 annual result came in at $8.3 million, down 4.88% from the prior year.
• Other Non-Current Assets grew to $8.5 million in Q3 2024 per SXTC's latest filing, from $8.3 million in the prior quarter.
• Over the last five years, Other Non-Current Assets for SXTC reached as high as $9.5 million in Q1 2022 and fell as low as $2.9 million in Q3 2020.
• A 5-year average of $8.1 million and a median of $8.6 million in 2023 frame the typical range for Other Non-Current Assets.
• Annual changes were most pronounced in 2021 — Other Non-Current Assets soared 225.9% — and 2022, when it retreated 9.42%.
• Year by year, Other Non-Current Assets stood at $2.9 million in 2020, then surged by 225.9% to $9.3 million in 2021, then slipped by 9.42% to $8.4 million in 2022, then grew by 3.58% to $8.7 million in 2023, then slipped by 2.14% to $8.5 million in 2024.
• According to Business Quant data, Other Non-Current Assets over the past three periods registered $8.5 million, $8.3 million, and $8.7 million for Q3 2024, Q1 2024, and Q1 2023 respectively.